PTC Therapeutics (NASDAQ:PTCT – Get Rating) had its target price decreased by Credit Suisse Group from $55.00 to $50.00 in a research note published on Wednesday, The Fly reports. A number of other equities research analysts also recently issued reports on the stock. StockNews.com initiated coverage on shares of PTC Therapeutics in a research report […]